新型冠状病毒疾病：抗病毒药物、抗体及中药研究进展 | VS推荐

新型冠状病毒疾病：抗病毒药物、抗体及中药研究进展

（点击阅读全文）

作者：

管文艺，蓝文东，张静，赵珊，欧俊贤，吴晓薇，严雨茜，吴建国，张其威

单位：

1. 南方医科大学公共卫生学院

2. 暨南大学病原微生物研究院

3.广东省病毒学重点实验室

摘要：世界卫生组织（WHO）宣布2019年底出现的由新型冠状病毒SARS-CoV-2引起的冠状病毒疾病（COVID-19）是第一个冠状病毒全球大流行。目前世界上还未出现有效的抗SARS-CoV-2药物获批用于治疗COVID-19患者，因此迫切需要提供多种治疗选择应对新冠病毒疾病暴发。为促进新冠肺病毒治疗药物的更好和更快发展，并为临床治疗提供参考意见，我们在此介绍一些有发展前景的治疗药物，包括现存的抗病毒药物的老药新用、基于网络的药理学研究、抗体开发和中药发展。其中部分药物已进入最后一个临床试验阶段。

Abstract: The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing—phase III–IV clinical trials.

（点击阅读全文）

扩展阅读：